This post will be about Annovis Bio (ANVS) –
Current stock price – $12.52
Current market cap – $140 million
Why Annovis Bio?
For the past 30 years, big pharma has struggled to come up with effective treatments for extremely complex neurodegenerative diseases such as Alzheimer's and Parkinson's Disease.
There have been countless failed clinical studies and useless and failed drugs in this space, FDA scandals, etc.
There is huge unmet need for effective treatment options that result in cognitive improvement and slowing decline of Alzheimer's and Parkinson's patients
Currently there are only 2 available drugs in the entire world that show any sort of results in slowing the progression of Alzheimer's and Parkinson's – Recently FDA approved Kisluna by Eli Lilly and Leqembi by BioGen.
These 2 drugs work “somewhat” – however they don't actually treat the underlying disease, they simply just slow progression.
In comes Annovis Bio.
Annovis Bio is an extremely small company of 14 or so employees.
The CEO, Dr. Maria Maccecchini, has dedicated her entire life's work to studying Alzheimer's, Parkinson's Disease, Lewy Body Dementia, etc.
Currently Annovis Bio has been carrying their main pipeline drug candidate Buntanetap through clinical trials for both Alzheimer's and Parkinson's Disease.
They are in Phase 2/3 for Alzheimer's and Phase 3 for Parkinson's Disease
Early Alzheimer's data is extremely good. More data to come soon.
2 weeks ago, Annovis Bio presented Phase 3 data for Parkinson's Disease.
The data completely knocked it of the park.
The stock price went from $5 to $17 in a matter of days.
The data so far points to Buntanetap being the best drug in the world for Parkinson's Disease and most likely for Alzheimer's too. (The same drug works for both diseases).
Parkinson's patients walked into clinical trials using a walker or a cane or wheelchair and left the trials walking out on their own 2 feet. The drug worked so well that doctors were actually accusing these patients of faking having Parkinson's disease.
First hand accounts from patients in the clinical trials say that the drug is simply amazing. They feel better, they have improved cognition, motor skills, and feel less anxiety, and there are literally ZERO negative side effects in any patient. Other neurosegenerative drugs from other pharma companies have resulted in brain swelling, brain bleeding, and death.
Annovis's Buntanetap has ZERO negative side effects. Combined with best results seen so far in history based on clinical data so far. The drug really works. It actually improves cognition, not just slow progression of decline. Something not many have accomplished in 30 years of research.
And Buntanetap is only a once daily pill, not an injection like other treatment options available
Annovis Bio CEO mentioned in the latest investor call that big investors are eyeing the company and partnerships are in talks now. They have many interested parties for either a buyout by big pharma, a partnership with major countries or companies, royalties companies, bankers, etc. They are just waiting for FDA nod of approval, which seems all but guaranteed at this point based on the amazing data with no negative side effects at all.
Annovis Bio meets with the FDA in September where they plan to submit a NDA (new drug application) for fast track approval for Parkinson's, and meets with the FDA again in October for Alzheimer's.
They also are set to receive $40 million dollars in NIH grants in Q1 2025.
Annovis Bio just recently hired 4 new executives, all who have backgrounds at big pharma such as Pfizer, as well as with the federal government such as NIH, CDC, FDA, etc.
Keep in mind this is a company with only 10 employees prior to these hires last week. Now they have 14 employees.
Small companies don't hire 4 executives from big pharma for no reason.
The stock price has surged from $5 to $17 last week on all of this news with insane amounts of volume (highest in history of the stock) and now has retraced back to around $12.
As I said market cap is still only $140 million. It was only $50 million 2 weeks ago.
This is a 10 bagger in a short time frame. Just my opinion. Do your own research but this should give you a solid introduction to the best in class drug Annovis Bio is developing for Alzheimer's and Parkinson's which has a lot of unmet need and is potentially the best drug in the world for neurodegenerative disease, even beating out Eli Lilly's newly approved drug Kisluna, which only offers symptomatic relief, not disease modification and cognitive improvements like Annovis's Buntanetap. People in clinical trials are asking for more of this drug and an open label study is being planned for patients who are getting amazing benefits of this new drug while it receives approval from the FDA
Leave a Reply